NEW YORK, May 23 (GenomeWeb News) - Ortho-McNeil Pharmaceutical has licensed another part of Cellzome's proteomics-based Alzheimer's disease program, exercising an option under the terms of a collaboration signed between the two companies in March, Cellzome said today.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.